Dr. Jorge Cortes, a renowned expert on CML and Chair of the CML Section at MD Anderson Center explains the latest news on existing and emerging treatments. This includes encouraging long-term follow-up for CML patients taking second generation tyrosine kinase inhibitors (TKIs). Dr. Cortes also comments on whether patients who are doing well on the original TKI, Gleevec, should switch. He also explains the latest information on a promising treatment in trials, Ponatinib, and the hope it gives patients who become resistant to TKIs or who have the T315i mutation not treated effectively by the approved TKIs. Dr. Cortes also comments on other drugs up for FDA review, Bosutinub and Omacetaxine, and explains which patients might benefit.

From www.patientpower.info